XORTX Therapeutics (XRTX) Change in Receivables (2021 - 2026)
XORTX Therapeutics' (XRTX) quarterly Change in Receivables came in at $15539.0 in Q1 2026, up 3936.1% YoY from $385.0 in Q1 2025, and up 126.75% on a QoQ basis from -$58080.0 in Q4 2025.
XORTX Therapeutics (XRTX) Change in Receivables (2021 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 6 years of Change in Receivables data on file, last reported at $15539.0 in Q1 2026.
- Quarterly Change in Receivables rose 3936.1% year-over-year to $15539.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47381.0 (down 447.6% YoY) and the FY2025 annual result came in at -$62535.0, down 245.18% from the prior year.
- Change in Receivables advanced to $15539.0 in Q1 2026, from -$58080.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $124837.0 in Q3 2022 to a low of -$82291.0 in Q1 2022.
- A 5-year average of -$1856.2 and a median of $6007.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2025 — Change in Receivables plunged 1183.25% — and 2026, when it surged 3936.1%.
- Tracing XRTX's Change in Receivables over 5 years: stood at -$17816.4 in 2022, then soared by 142.26% to $7530.0 in 2023, then sank by 160.11% to -$4526.0 in 2024, then sank by 1183.25% to -$58080.0 in 2025, then jumped by 126.75% to $15539.0 in 2026.
- The last three Change in Receivables figures came in at $15539.0 (Q1 2026), -$58080.0 (Q4 2025), and -$11232.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 15,539.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,539.00 |
| Mar 31, 2026 | 15,539.00 |
| Dec 31, 2025 | -58,080.00 |
| Dec 31, 2025 | -58,080.00 |
| Sep 30, 2025 | -11,232.00 |
| Sep 30, 2025 | -11,232.00 |
| Jun 30, 2025 | 6,392.00 |
| Jun 30, 2025 | 6,392.00 |
| Mar 31, 2025 | 385.00 |
| Mar 31, 2025 | 385.00 |
| Dec 31, 2024 | -4,526.00 |
| Dec 31, 2024 | -4,526.00 |
| Sep 30, 2024 | 9,696.00 |
| Sep 30, 2024 | 9,696.00 |
| Jun 30, 2024 | 8,076.00 |
| Jun 30, 2024 | 8,076.00 |
| Mar 31, 2024 | 29,828.00 |
| Mar 31, 2024 | 29,828.00 |
| Dec 31, 2023 | 7,530.00 |
| Dec 31, 2023 | 7,530.00 |